191 related articles for article (PubMed ID: 22851407)
1. Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.
Verschraegen CF; Czok S; Muller CY; Boyd L; Lee SJ; Rutledge T; Blank S; Pothuri B; Eberhardt S; Muggia F
Ann Oncol; 2012 Dec; 23(12):3104-3110. PubMed ID: 22851407
[TBL] [Abstract][Full Text] [Related]
2. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
3. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
5. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
6. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
[TBL] [Abstract][Full Text] [Related]
8. Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.
Vergote IB; Garcia A; Micha J; Pippitt C; Bendell J; Spitz D; Reed N; Dark G; Fracasso PM; Ibrahim EN; Armenio VA; Duska L; Poole C; Gennigens C; Dirix LY; Leung AC; Zhao C; Soufi-Mahjoubi R; Rustin G
J Clin Oncol; 2013 Nov; 31(32):4060-6. PubMed ID: 24081946
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
Wenham RM; Lapolla J; Lin HY; Apte SM; Lancaster JM; Judson PL; Gonzalez-Bosquet J; Herschberger A; Havrilesky LJ; Secord AA
Gynecol Oncol; 2013 Jul; 130(1):19-24. PubMed ID: 23623830
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
[TBL] [Abstract][Full Text] [Related]
12. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers.
Kudoh K; Takano M; Kouta H; Kikuchi R; Kita T; Miyamoto M; Watanabe A; Kato M; Goto T; Kikuchi Y
Gynecol Oncol; 2011 Aug; 122(2):233-7. PubMed ID: 21601912
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
14. Panitumumab and pegylated liposomal doxorubicin in platinum-resistant epithelial ovarian cancer with KRAS wild-type: the PaLiDo study, a phase II nonrandomized multicenter study.
Steffensen KD; Waldstrøm M; Pallisgård N; Lund B; Bergfeldt K; Wihl J; Keldsen N; Marth C; Vergote I; Jakobsen A
Int J Gynecol Cancer; 2013 Jan; 23(1):73-80. PubMed ID: 23211422
[TBL] [Abstract][Full Text] [Related]
15. Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
Lee JY; Park JY; Park SY; Lee JW; Kim JW; Kim YB; Jeong DH; Lee KB; Kim TH; Lee IH; Choi MC; Kim KH; Kim YM; Lee YJ; Kang S; ; Pujade-Lauraine E
Gynecol Oncol; 2019 Jan; 152(1):61-67. PubMed ID: 30409490
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma.
Tillmanns TD; Lowe MP; Walker MS; Stepanski EJ; Schwartzberg LS
Gynecol Oncol; 2013 Feb; 128(2):221-8. PubMed ID: 22960352
[TBL] [Abstract][Full Text] [Related]
17. A phase 3 trial of bevacizumab in ovarian cancer.
Perren TJ; Swart AM; Pfisterer J; Ledermann JA; Pujade-Lauraine E; Kristensen G; Carey MS; Beale P; Cervantes A; Kurzeder C; du Bois A; Sehouli J; Kimmig R; Stähle A; Collinson F; Essapen S; Gourley C; Lortholary A; Selle F; Mirza MR; Leminen A; Plante M; Stark D; Qian W; Parmar MK; Oza AM;
N Engl J Med; 2011 Dec; 365(26):2484-96. PubMed ID: 22204725
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer.
Kavanagh JJ; Levenback CF; Ramirez PT; Wolf JL; Moore CL; Jones MR; Meng L; Brown GL; Bast RC
J Hematol Oncol; 2010 Mar; 3():9. PubMed ID: 20222977
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
Moroney J; Fu S; Moulder S; Falchook G; Helgason T; Levenback C; Hong D; Naing A; Wheler J; Kurzrock R
Clin Cancer Res; 2012 Oct; 18(20):5796-805. PubMed ID: 22927482
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: A retrospective analysis.
Wright JD; Hagemann A; Rader JS; Viviano D; Gibb RK; Norris L; Mutch DG; Powell MA
Cancer; 2006 Jul; 107(1):83-9. PubMed ID: 16736514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]